Department of Pharmacology and Toxicology, Faculty of Pharmacy, Pharmacy Collage, Umm Al-Qura University, Makkah, 21955, Saudi Arabia.
Pharmacy Collage, Umm Al-Qura University, Makkah, Saudi Arabia.
World J Pediatr. 2022 Feb;18(2):83-90. doi: 10.1007/s12519-021-00499-w. Epub 2022 Jan 4.
Multisystem inflammatory syndrome in children (MIS-C) is a serious health condition that develops from and is linked to coronavirus disease 2019. MIS-C is considered a multi-organ dysfunction involving cardiac, renal, respiratory, hematologic, gastrointestinal and neurological symptoms and groups of signs and symptoms such as rash or bilateral non-purulent conjunctivitis, hypotension or shock and acute gastrointestinal problems, which require immediate therapeutic intervention to prevent the aggravation of the patient's health condition. MIS-C is relatively new in the field of evidence-based medicine; however, there are several clinical guidelines for good clinical practice. For every disorder, the guidelines have different suggestions. Hence, based on the current status of the evidence, recommendations have been combined to form a unified guideline for therapeutic management.
This paper compares and evaluates the current MIS-C-specific clinical practice guidelines (namely, American Academy of Pediatrics, American College of Rheumatology, Helen DeVos Children's Hospital Foundation, Children's Hospital of The King's Daughters, and the Infectious Diseases Society of America). The compiled literature was then assessed by the authors separately, and an algorithm was proposed for each disorder, taking into consideration the various guidelines proposed for the management of the disorder.
The features of MIS-C patients are unified; this is very helpful in managing its symptoms and decreasing mortality rates. In addition, recommendations for pharmacological treatment for MIS-C symptoms are formulated after cross-comparison across five different guidelines.
This study provides a general interpretation of the results in the context of other evidence and implications for future research. It proposes a unified guideline based on the current evidence, with the best potential to maintain suitable clinical standards in the Saudi Arabian Ministry of Health.
儿童多系统炎症综合征(MIS-C)是一种严重的健康状况,由 2019 年冠状病毒病发展而来,并与之相关。MIS-C 被认为是一种多器官功能障碍,涉及心脏、肾脏、呼吸、血液、胃肠道和神经系统症状以及皮疹或双侧非脓性结膜炎、低血压或休克和急性胃肠道问题等体征和症状群,需要立即进行治疗干预,以防止患者病情恶化。MIS-C 在循证医学领域相对较新,但有几个临床指南用于良好的临床实践。对于每种疾病,指南都有不同的建议。因此,根据当前证据状况,将建议结合起来,形成一个统一的治疗管理指南。
本文比较和评估了目前针对 MIS-C 的特定临床实践指南(即美国儿科学会、美国风湿病学会、海伦·德沃斯儿童医院基金会、国王女儿儿童医院和传染病学会)。然后,作者分别对汇编的文献进行评估,并针对每种疾病提出了一个算法,同时考虑了为该疾病管理提出的各种指南。
MIS-C 患者的特征是统一的;这对于管理其症状和降低死亡率非常有帮助。此外,还针对 MIS-C 症状的药物治疗建议进行了交叉比较,制定了五个不同指南中的建议。
本研究在其他证据的背景下对结果进行了一般性解释,并对未来研究提出了建议。它根据当前证据提出了一个统一的指南,最有可能在沙特阿拉伯卫生部维持适当的临床标准。